LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
| Autor: | Janjigian, Y.Y., Ajani, J.A., Moehler, M., Garrido, M., Gallardo, C., Shen, L., Yamaguchi, K., Wyrwicz, L., Skoczylas, T., Bragagnoli, A., Liu, T., Tehfe, M., Elimova, E., Li, M., Poulart, V., Lei, M., Kondo, K., Shitara, K. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S1329-S1330 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|